4331 - 4340 of 5832 Results
Title
Year
- Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles2017OPENTitle: Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particlesJournal Name: PLOS ONEPublisher: Public Library of Science (PLoS)Vol: 12Issue #: 8Start Page: e0181844End Page: e0181844Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1371/journal.pone.0181844Best OA location URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181844&type=printableCitation Count: 28
- Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy2017OPENTitle: Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 44Issue #:Start Page: 13End Page: 17Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2017.08.006Best OA location URL: http://www.prd-journal.com/article/S1353802017302870/pdfCitation Count: 24
-
OPENTitle: Beliefs About Use of Complementary Health Approaches for Parkinson's DiseaseJournal Name: Holistic Nursing PracticePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 31Issue #: 5Start Page: 290End Page: 294Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1097/hnp.0000000000000229Best OA location URL: https://europepmc.org/articles/pmc5664950?pdf=renderCitation Count: 0
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial2017OPENTitle: Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialJournal Name: The LancetPublisher: Elsevier BVVol: 390Issue #: 10103Start Page: 1664End Page: 1675Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(17)31585-4Best OA location URL: https://europepmc.org/articles/pmc5831666?pdf=renderCitation Count: 641
- Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease2017OPENTitle: Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s diseaseJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-017-07181-0Best OA location URL: https://www.nature.com/articles/s41598-017-07181-0.pdfCitation Count: 106
-
OPENTitle: BRAPH: A graph theory software for the analysis of brain connectivityJournal Name: PLOS ONEPublisher: Public Library of Science (PLoS)Vol: 12Issue #: 8Start Page: e0178798End Page: e0178798Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1371/journal.pone.0178798Best OA location URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178798&type=printableCitation Count: 206
-
OPENTitle: Establishing the role of rare coding variants in known Parkinson's disease risk lociJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 59Issue #:Start Page: 220.e11End Page: 220.e18Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2017.07.009Best OA location URL: https://orca.cardiff.ac.uk/id/eprint/109440/1/Establishing%20the%20role%20of%20rare%20coding%20variants%20in%20known%20Parkinson.pdfCitation Count: 17
-
OPENTitle: mzStudio: A Dynamic Digital Canvas for User-Driven Interrogation of Mass Spectrometry DataJournal Name: ProteomesPublisher: MDPI AGVol: 5Issue #: 3Start Page: 20End Page: 20Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/proteomes5030020Best OA location URL: https://www.mdpi.com/2227-7382/5/3/20/pdf?version=1501590909Citation Count: 23
- Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia2017OPENTitle: Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementiaJournal Name: Alzheimer's Research & TherapyPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13195-017-0276-4Best OA location URL: https://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0276-4Citation Count: 114
- Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis2017OPENTitle: Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling AnalysisJournal Name: Clinical and Translational SciencePublisher: WileyVol: 11Issue #: 1Start Page: 63End Page: 70Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1111/cts.12492Best OA location URL: https://doi.org/10.1111/cts.12492Citation Count: 42